Dorrapharma is engaged in R&D, manufacture and market of intermediates, API and formulation. The services supplied are included in material sourcing, route selection, process & analytical development, custom synthesis and etc.
The API sites are approved by CFDA, PMDA, EU authorities and the total reactor capacity is 2,000,000L and the output is about 5,000 tons per year. The therapeutic areas cover anti-infection, anti-virus, digestive system, cardiovascular system and etc.
more >
Year of Establishment:
2011
Total Assets(USD):
Total Number of Staff:
10-50
Main Competitive Advantages:
Experienced R&D Staff,Production Capacity,Contract Manufacturing (CRO,CMO),Quality Service
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
R&D capacity:
Own Brand
Annual Turnover(USD):
Main Sales Markets:
North America,Western Europe,Eastern Europe,Asia
Other Competitive Advantages:
Patents and Copyrights: